scholarly journals The impact of antinuclear antibodies induced by anti-tumour necrosis factor alpha (anti-TNF-α) agents on the long-term treatment outcomes in rheumatoid arthritis patients

2021 ◽  
Author(s):  
Daniela Oliveira ◽  
Ana Martins ◽  
Frederico Martins ◽  
Maria Rato ◽  
Filipe Pinheiro ◽  
...  
2011 ◽  
Vol 3 ◽  
pp. CMT.S1978
Author(s):  
Manuela Marzo ◽  
Carla Felice ◽  
Gian Lodovico Rapaccini ◽  
Luisa Guidi ◽  
Alessandro Armuzzi

Infliximab is a chimeric monoclonal antibody against anti-tumour necrosis factor alpha that has changed the management of inflammatory bowel diseases. Our review describes its mean clinical and pharmacological features, in order to resume its efficacy in induction and maintenance of clinical remission in both Crohn's Disease and Ulcerative Colitis. Although its efficacy in induction and maintenance of remission has been established by several clinical trials, the administration of Infliximab is also associated with an increased risk of side effects, in particular in long-term treatment. We also discussed about issues regarding the correct timing to start and to stop biological therapy.


2020 ◽  
pp. 205064062097740
Author(s):  
Stefano Festa ◽  
Maria L Scribano ◽  
Daniela Pugliese ◽  
Cristina Bezzio ◽  
Mariabeatrice Principi ◽  
...  

Background The long-term course of ulcerative colitis after a severe attack is poorly understood. Second-line rescue therapy with cyclosporine or infliximab is effective for reducing short-term colectomy but the impact in the long-term is controversial. Objective The purpose of this study was to evaluate the long-term course of acute severe ulcerative colitis patients who avoid early colectomy either because of response to steroids or rescue therapy. Methods This was a multicentre retrospective cohort study of adult patients with acute severe ulcerative colitis admitted to Italian inflammatory bowel disease referral centres from 2005–2017. All patients received intravenous steroids, and those who did not respond received either rescue therapy or colectomy. For patients who avoided early colectomy (within three months from the index attack), we recorded the date of colectomy, last follow-up visit or death. The primary end-point was long-term colectomy rate in patients avoiding early colectomy. Results From the included 372 patients with acute severe ulcerative colitis, 337 (90.6%) avoided early colectomy. From those, 60.5% were responsive to steroids and 39.5% to the rescue therapy. Median follow-up was 44 months (interquartile range, 21–85). Colectomy-free survival probability was 93.5%, 81.5% and 79.4% at one, three and five years, respectively. Colectomy risk was higher among rescue therapy users than in steroid-responders (log-rank test, p = 0.02). At multivariate analysis response to steroids was independently associated with a lower risk of long-term colectomy (adjusted odds ratio = 0.5; 95% confidence interval, 0.2–0.8), while previous exposure to anti-tumour necrosis factor alpha agents was associated with an increased risk (adjusted odds ratio = 3.0; 95% confidence interval, 1.5–5.7). Approximately 50% of patients required additional therapy or new hospitalization within five years due to a recurrent flare. Death occurred in three patients (0.9%). Conclusions Patients with acute severe ulcerative colitis avoiding early colectomy are at risk of long-term colectomy, especially if previously exposed to anti-tumour necrosis factor alpha agents or if rescue therapy during the acute attack was required because of steroid refractoriness.


2009 ◽  
Vol 64 (1-2) ◽  
pp. 32-36 ◽  
Author(s):  
Camila B. de A. Carli ◽  
Djamile C. de Matos ◽  
Flávia C. M. Lopes ◽  
Danielle C. G. Maia ◽  
Maristela B. Dias ◽  
...  

1The purpose of the present study was to investigate antitumour and anti-inflammatory activities of flavonoids isolated from Byrsonima crassa, Davilla elliptica and Mouriri pusa. The antitumour activity was measured by the MTT assay in murine mammary tumour cells (LM2) and the IC50 values of the fl avonoids tested ranged from (31.5 ± 2.97) to (203.1 ± 5.9) μg/ml. The fl avonoids (myricetin-3-O-α-L-rhamnopyranoside) and 3 (quercetin-3-Ogalactopyranoside) from D. elliptica were the most active ones against the tumour cells. The same samples were tested to determine the inhibition of the release of nitric oxide (NO) and of the tumour necrosis factor-alpha (TNF-α) in murine macrophages by the Griess and ELISA sandwich assay, respectively. Almost all the samples showed inhibitory activity to the release of NO but not of TNF-α. Of all substances tested, flavonoids 2 (quercetin) and 6 (myricetin) may show promising activity in the treatment of murine breast cancer by immunomodulatory and antiproliferative activities.


Sign in / Sign up

Export Citation Format

Share Document